Aurinia Pharmaceuticals Inc. announced a definitive agreement to acquire Kezar Life Sciences, Inc. for $6.955 in cash per share, plus a contingent value right (CVR) that could provide additional payments based on the future performance of Kezar’s assets. The transaction values Kezar at roughly $50 million in cash, a figure derived from the per‑share price and the number of outstanding shares, and represents a premium over Kezar’s recent trading levels.
The deal structure requires Aurinia to tender shares representing at least a majority of Kezar’s outstanding shares and for Kezar to have closing net cash in excess of $50 million. The CVR is tied to the commercial success of Kezar’s lead program, zetomipzomib, and to proceeds from other portfolio assets, providing upside to Kezar shareholders if the assets perform well after the acquisition.
Strategically, the acquisition expands Aurinia’s autoimmune portfolio. Aurinia already markets LUPKYNIS® for lupus nephritis; adding zetomipzomib, a first‑in‑class immunoproteasome inhibitor with promising Phase 2 data in autoimmune hepatitis and lupus nephritis, strengthens its position in this therapeutic area and aligns with Aurinia’s focus on kidney and autoimmune diseases.
Kezar has faced significant regulatory setbacks, including FDA holds on zetomipzomib and workforce reductions, and reported net losses in recent quarters. As of September 30 2025, Kezar held $90.2 million in cash and securities, and the acquisition provides the company with immediate liquidity while allowing Aurinia to absorb Kezar’s pipeline and address its financial challenges.
Aurinia’s recent Q4 2025 earnings beat expectations, with an EPS of $0.26 versus analysts’ estimate of $0.21, reflecting strong execution and cost control. The company’s cash position and profitability give it the capacity to fund the acquisition, while Kezar’s shareholders receive a premium and potential upside through the CVR, addressing Kezar’s need for capital to navigate its regulatory hurdles.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.